Haemonetics Corp. (HAE) Financials Nov 20, 2014, 4:33

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Haemonetics Corp. (HAE) Financials Nov 20, 2014, 4:33 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Haemonetics Corp.


Fiscal year is April-March. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 645.43M 676.69M 727.84M 891.99M 938.51M
Cost of Goods Sold (COGS) incl. D&A 307.95M 321.49M 358.6M 463.86M 477.14M
COGS excluding D&A 264.71M 273.34M 308.64M 398.38M 395.4M
Depreciation & Amortization Expense 43.24M 48.15M 49.97M 65.48M 81.74M
Depreciation 35.5M 37M 38.6M 43.38M 52.54M
Amortization of Intangibles 7.74M 11.15M 11.37M 22.1M 29.2M
Gross Income 337.48M 355.21M 369.24M 428.13M 461.37M
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 240.86M 247.32M 272.46M 323.5M 323.98M
Research & Development 26.38M 32.66M 36.8M 44.39M 50.6M
Other SG&A 214.48M 214.67M 235.66M 279.11M 273.38M
Other Operating Expense 0 0 0 0 0
Unusual Expense 12.81M (838,000) 8.02M 48.46M 90.06M
EBIT after Unusual Expense (12.81M) 838,000 (8.02M) (48.46M) (90.06M)
Non Operating Income/Expense (2.2M) 980,000 740,000 (371,000) (2.03M)
Non-Operating Interest Income 399,000 384,000 - 0 0
Equity in Affiliates (Pretax) 0 0 0 - -
Interest Expense 742,000 6,000 - 5.9M 8.9M
Gross Interest Expense 742,000 6,000 - 6.2M 9.3M
Interest Capitalized - 0 0 300,000 400,000
Pretax Income 81.27M 110.08M 89.5M 49.9M 36.4M
Income Tax 22.9M 30.1M 22.61M 11.1M 1.25M
Income Tax - Current Domestic 10.98M 17.09M 10.78M 5.12M (4.02M)
Income Tax - Current Foreign 9.33M 7.23M 5.95M 5.39M 5.48M
Income Tax - Deferred Domestic 4.36M 5.37M 6.93M 1.42M (1.58M)
Income Tax - Deferred Foreign (1.77M) 413,000 (1.05M) (826,000) 1.38M
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 - -
Other After Tax Income (Expense) - - - 0 0
Consolidated Net Income 58.37M 79.98M 66.89M 38.8M 35.15M
Minority Interest Expense 0 0 0 0 0
Net Income 58.37M 79.98M 66.89M 38.8M 35.15M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 58.37M 79.98M 66.89M 38.8M 35.15M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 58.37M 79.98M 66.89M 38.8M 35.15M
EPS (Basic) 1.15 1.60 1.32 0.76 0.68
Basic Shares Outstanding 50.9M 50.15M 50.73M 51.35M 51.61M
EPS (Diluted) 1.12 1.56 1.30 0.74 0.67
Diluted Shares Outstanding 52.13M 51.19M 51.59M 52.26M 52.38M
EBITDA 139.86M 156.03M 146.74M 170.11M 219.13M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

HeartCore's Journey: From Nasdaq Challenges to Growth Potential

Updated Category News Views 35

HeartCore's Nasdaq Delisting Challenge HeartCore Enterprises, Inc. (NASDAQ:HTCR), a provider of enterprise software and consulting services, is currently facing a significant challenge related to its listing on the Nasdaq Capital Market. The company has received notice of non-compliance with the minimum bid price requirement, which mandates that its stock price must be at...

Continue Reading
Mitchell Capital Expands Portfolio with Optelos Acquisition

Updated Category News Views 236

Mitchell Capital's New Acquisition of Optelos Mitchell Capital, a prominent private equity firm, recently announced a significant acquisition that marks a pivotal moment for their long-term investment strategy. They have secured a controlling interest in Optelos, a distinguished provider of digital twin platforms that are tailored for enhancing critical infrastructure...

Continue Reading
Tampa Bay Lightning and Scripps Sports Forge Exciting Partnership

Updated Category News Views 247

Partnership Announcement Between Tampa Bay Lightning and Scripps Sports The Tampa Bay Lightning have officially entered into an exciting multi-year partnership with Scripps Sports. This collaboration signifies a new chapter for the Tampa Bay Lightning, expanding their reach in broadcasting and enhancing viewer engagement with National Hockey League (NHL) games. Through...

Continue Reading
Kazia Therapeutics Sets Meeting with FDA on Glioblastoma Treatment

Updated Category News Views 61

Kazia Therapeutics Prepares for FDA Meeting on Paxalisib Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is set to meet with the U.S. Food and Drug Administration (FDA) to explore potential pathways for the registration of its innovative drug, Paxalisib, aimed at treating newly diagnosed glioblastoma multiforme (GBM). This crucial...

Continue Reading
Important Notice for Flux Power Investors on Lead Plaintiff Claims

Updated Category News Views 100

Overview of Flux Power Investor Claims Investors with concerns regarding their investments in Flux Power Holdings, Inc. (NASDAQ: FLUX) have much to consider as recent developments unfold. The national securities law firm, Faruqi & Faruqi, LLP, is actively investigating claims that could impact investor interests and is eager to assist those affected. Critical Investment...

Continue Reading